<DOC>
	<DOC>NCT01099540</DOC>
	<brief_summary>To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.</brief_summary>
	<brief_title>Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>neuroendocrine tumor</keyword>
</DOC>